Dasatinib medical insurance reimbursement ratio

It is understood that the original drug of Dasatinib (Dasatinib) is already on the market in China. According to the relevant regulations of the National Medical Insurance Administration, the original drug has been included in the reimbursement scope of Class B medical insurance. Reimbursement is limited to eligible patients, that is, chronic myeloid cells that are resistant or intolerant to imatinib. For patients with leukemia (CML), eligible patients need to purchase drugs at the local medical insurance bureau for reimbursement based on the prescription information. The common specifications of the original drug are 50mg*60 tablets per box, which may cost around 10,000 yuan. Due to differences in reimbursement ratios, the reimbursement prices may be different, and patients who do not meet the conditions can only purchase the drug at their own expense.